ASCO 2023 | CRUX: safety of ruxolitinib in newly-diagnosed high-grade gliomas

Manmeet Ahluwalia, MD, MBA, FASCO, Baptist Health South Florida, Miami, FL, presents findings from a toxicity report of a Phase I trial (NCT03514069) of ruxolitinib, a JAK inhibitor, with radiotherapy in patients with newly-diagnosed high-grade gliomas. Patients with MGMT unmethylated and methylated gliomas received ruxolitinib and radiotherapy with and without temozolomide respectively. Ruxolitinib and radiotherapy with temozolomide is a promising therapy, where no dose limiting toxicities were reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.